Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Pregnancy Tests Evaluated During Early Gravidity

By LabMedica International staff writers
Posted on 22 Apr 2014
The predominant hormone human chorionic gonadotropin (hCG) variant in urine, hCG β core fragment (hCGβcf), has been demonstrated to cause false-negative results in qualitative point-of-care (POC) hCG devices.

In a hospital setting, failure to detect pregnancy can lead to major consequences such as administration of medications that cause birth defects, fetal radiation exposure, or failure to diagnose ectopic pregnancy, which is the leading cause of first-trimester pregnancy-related maternal death.

Scientists at Washington University School of Medicine (St. More...
Louis, MO, USA) tested a wide range of purified hCG and hCGβcf concentrations, which were mixed and tested on two POC devices. By use of those results, a screening method was defined and nine additional POC devices were evaluated. Two solutions containing 500 pmol/L (171 IU/L) intact hCG without hCGβcf and 500 pmol/L intact hCG with 500,000 pmol/L hCGβcf were used to screen all POC devices.

Varying concentrations of intact hCG and hCGβcf were combined in an hCG-negative urine matrix. Each solution was tested in duplicate by use of the SP hCG Combo Rapid Test (Cardinal Health; Dublin, OH, USA) and the OSOM hCG Combo Test (OSOM; Lexington, MA, USA). This screening method was then used to evaluate the performance of nine additional qualitative hCG POC devices. Visible differences in device performance were evident, resulting in the classification of the devices into three distinct groups: best performance, moderate performance, and poor performance.

The two best-performing devices were the Beckman Coulter Icon 20 (Brea, CA, USA) and the Alere hCG Combo (Waltham, MA, USA). The Icon 20 was the only device to exhibit an increased signal when hCGβcf was added to intact hCG. The Alere device was very modestly affected by the addition of hCGβcf. Two other tests present an unacceptable risk of false-negative results to patients after 5–7 weeks of pregnancy and the accuracy of the remaining seven tests was moderately affected by hCG beta core fragment.

Ann M. Gronowski, PhD, the senior author of the study said, “There are three important take home messages here. One, physicians, nurses, and other healthcare professionals need to be educated that this is a problem. Two, manufacturers need to make the possibility of false negatives clearly visible in their package inserts and work to develop better tests. And three, in centers where quantitative blood hCG testing is available, this should be the preferred pregnancy test. Blood testing is not subject to this effect because hCG beta core fragment is not present in serum.” The study was published in the April 2014 issue of the journal Clinical Chemistry.

Related Links:

Washington University School of Medicine 
Cardinal Health
Beckman Coulter




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
All-in-One Molecular System
AIO M160
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.